pCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics Baylor College of Medicine
Jan 17, 2018
pCRRT Multi-Center Registry Data Effective April 1, 2002
Multi-Center Pediatric CRRT Registry
Stuart L. Goldstein, MDAssistant Professor of Pediatrics
Baylor College of Medicine
pCRRT Multi-Center Registry Data Effective April 1, 2002
Overview
• Registry study phases– Study design– Study aims
• Current participating centers– Institutional practice protocol variation
• Current data analysis
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry: Phase 1 Design
• Collect prospective data from 5 to 10 pediatric centers treating 15 to 20 patients annually (200-300 patients over 3 years)
• Each center follows own institutional practice– Patient selection– Initiation and termination– Anti-coagulation protocols– Convection versus diffusion versus hemodiafiltration– Fluid composition
• Cytokine clearance study
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry: Phase 1 Aims
• Assess for potential associations between various practices and pediatric patient outcomes
• Assess for potential associations between varying practices and CRRT machine functioning
• Determine CRRT clearance rates of various SIRS and CARS cytokines in children with sepsis
pCRRT Multi-Center Registry Data Effective April 1, 2002
Current Registry Centers and PI
• Texas Children’s Hospital (January 2001)• Boston Children’s Hospital (March 2001)• Seattle Children’s Hospital (July 2001)• Univ of Alabama Children’s (July 2001)• Univ of Michigan (December 2002)
• Stuart Goldstein, MD• Michael Somers, MD• Jordan Symons, MD• Timothy Bunchman, MD• Patrick Brophy, MD Melissa
Gregory, MD
pCRRT Multi-Center Registry Data Effective April 1, 2002
Pre-CRRT Registry Data
• Demographics– Primary disease, co-morbid illness, age, gender, days in PICU
• CRRT specifics– Treatment or prevention of fluid overload and/or electrolyte
imbalance– Access size and site
• Renal failure indices– GFR (Schwartz)– Percent fluid overload (%FO)– Urine output in previous 24 hours
pCRRT Multi-Center Registry Data Effective April 1, 2002
Registry PICU Data
• PRISM 2 at ICU admission and CRRT initiation• CRRT initiation
– CVP– MAP– Pressor number and specific drugs– Diuretic use
• CRRT course– Maximum pressor number– MAP change– Pressors weaned?
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry Circuit Data
• Separate data page for each circuit• Machine brand• Extracorporeal volume• Priming fluid
– NS– albumin– blood mixed with
• FFP, albumin, or bicarbonate
• Dialysis or replacement fluid composition– Normocarb™ (Dialysis Solutions, Inc)– Baxter hemofiltration fluid™– Saline, Ringer’s lactate, peritoneal dialysis fluid
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry Circuit Data• Anticoagulation
– Citrate– Heparin rate
• ACT measured per hour• Mean ACT• # ACT < 180 seconds
• Clearance prescription– CVVH versus CVVHD versus CVVHDF– ml/1.73m2/hour
• Nutrition prescription– Kcal/kg/day– Grams protein/kg/day
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry Patient Data: Outcome
• Survival versus death (discharge from PICU)• Attainment of target dry weight• Reason to discontinue CRRT
– Death– Regained renal function– Underlying illness resolved– Tolerates intermittent hemodialysis
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry Circuit Data: Outcome
• Filter life-span (hours)• Reason for circuit change
– clotting– access malfunction– machine malfunction– unrelated patient indication (e.g., needs CT scan)– CRRT discontinued
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry: Results (4/1/2002)
• 42 patients entered into study• 36 with complete data• 128 circuits• 4905 cumulative treatment hours
– Mean 41.2 + 28.9 hours– Range 1 to 118 hours
pCRRT Multi-Center Registry Data Effective April 1, 2002
Baseline Demographics
Age 8.2 + 7.3 years
Weight 33.8 + 28.4 kg
GFR 35.3 + 25.3 ml/min/1.73m2
pCRRT Multi-Center Registry Data Effective April 1, 2002
Registry Center Census
Center
Pat
ient
s
0
2
4
6
8
10
12
14
16
18
20
Houston Boston UAB Seattle
pCRRT Multi-Center Registry Data Effective April 1, 2002
Primary Disease
Primary Disease
Pat
ient
s
0
1
2
3
4
5
6
7
8
9
10
Sep
sis
Car
diom
yopa
thy
RV
T
BM
T
ATN
CV
Sho
ck
Tum
or L
ysis
AM
L
Bow
el P
erf
Met
abx
FO
MO
SF
Nep
hrtx
Met
abol
ic
AR
F
HU
S
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry Modality
MODALITY
Pat
ient
s
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
CVVH CVVHDF CVVHD SCUF
pCRRT Multi-Center Registry Data Effective April 1, 2002
Reason to Start CRRT
Reason to Start CRRT
Pat
ient
Num
ber
35.9% 35.9%
12.8%
7.7% 7.7%
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
FO Only FO and EI EI Only Other Prevention of FO
pCRRT Multi-Center Registry Data Effective April 1, 2002
Outcome
OUTCOME
Pat
ient
s
38.9%
61.1%
0
2
4
6
8
10
12
14
16
18
20
22
24
Death Survival
pCRRT Multi-Center Registry Data Effective April 1, 2002
Clinical Variables and Outcome• Survival not associated with
– GFR– Pressor number– MAP– PRISM at ICU admission– Age– Weight
• Survival associated with– PRISM at CRRT initiation– % Fluid overload at CRRT initiation
pCRRT Multi-Center Registry Data Effective April 1, 2002
PRISM at CRRT Initiation and Outcome
±Std. Dev.±Std. Err.Mean
OUTCOME
PR
ISM
AT
CR
RT
Initi
atio
n
2
6
10
14
18
22
26
30
Death Survival
P < 0.0005
pCRRT Multi-Center Registry Data Effective April 1, 2002
Fluid Overload and Outcome
±Std. Dev.±Std. Err.Mean
OUTCOME
Per
cent
Flu
id O
verlo
ad a
t CR
RT
Initi
atio
n
-5
0
5
10
15
20
25
30
35
40
Death Survival
P < 0.05
pCRRT Multi-Center Registry Data Effective April 1, 2002
Fluid Overload and Outcome:Renal Failure Only
±Std. Dev.±Std. Err.Mean
OUTCOME
Per
cent
Flu
id O
verlo
ad a
t CR
RT
Initi
atio
n
-5
0
5
10
15
20
25
30
35
40
Death Survival
P < 0.05
pCRRT Multi-Center Registry Data Effective April 1, 2002
Fluid Overload, Severity of Illness and Outcome
• Greater degrees of fluid overload associated with death, even when controlled for severity of illness by PRISM score (multiple regression analysis; p<0.03)
pCRRT Multi-Center Registry Data Effective April 1, 2002
Circuit Change Reason
Reason to Change Circuit
Circ
uit N
umbe
r
0
3
6
9
12
15
18
21
24
27
30
33
36
Scheduled ChangeClotted
OtherAccess Malfunction
Patient Test
pCRRT Multi-Center Registry Data Effective April 1, 2002
Anticoagulation Method and Circuit Life
±Std. Dev.±Std. Err.Mean
Anticoagulation
Circ
uit L
ife (H
ours
)
-10
10
30
50
70
90
Heparin Citrate
P < 0.003
N=69
N=38
pCRRT Multi-Center Registry Data Effective April 1, 2002
pCRRT Registry Future Phases• Assess association between nutrition and outcome• Assess cytokine levels and clearance• Test new products devices safely and efficiently• Prospective randomized trials
– Dose– Fluid options– Selective cytokine removal– Time to intervention– Disease-specific protocol and outcome
• Web-based for easy access and query